Ziyad Alzahrani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ziyad Alzahrani has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Muhanad Alzahrani
Department of Medicine, University of Maryland Medical Center, Baltimore, USA
4 shared publications - Abdullah Alabbasi
Ministry of Health, Jeddah, Saudi Arabia
3 shared publications - Mohammed Sayes
Department of Medicine, University of Utah, Salt Lake City, USA
2 shared publications - Rayyan Fahad Hamoud Altemani
Department of Medicine, University of Utah, Salt Lake City, USA
2 shared publications - Abdulhadi Jfri
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
1 shared publication Abdullah Aman
1 shared publication
Latest Publications
- Open Access
- 7 May 2026
- Published by American Society for Inclusion, Diversity, and Equity in Healthcare in ASIDE Oncology
- Vol. 1 (1) , 38-43
Divergent Temporal Trends in Site-Specific Sarcoma Mortality in the United States, 1999–2020: A Population-Based Analysis
Background: Sarcomas are heterogeneous malignancies with prognoses that vary markedly by anatomical site. Whether population-level mortality trends differ across anatomical locations remains unclear. Methods: Sarcoma-related deaths in the United States from 1999 to 2020 were analyzed using the CDC WONDER Underlying Cause of Death database. ICD-10 codes classified deaths into six anatomical categories: bone, retroperitoneal/peritoneal, trunk soft tissue, extremity soft tissue, head and neck, and unspecified. Negative binomial regression models with a population offset estimated site-specific trends, and an interaction model tested heterogeneity across sites. Sensitivity analyses excluded 2020 and recalculated proportions among specified-site deaths only. Results: Nearly half of the deaths were coded to unspecified sites (49.8%), with no improvement over time. Among specified sites, bone accounted for the largest share (22.6%), followed by retroperitoneal/peritoneal sarcomas (15.1%). Overall mortality increased by 1.32% annually (IRR 1.013, 95% CI 1.012–1.014), with significant increases across all specified sites. Decomposition showed that retroperitoneal/peritoneal (43.5%) and bone (29.7%) sarcomas contributed the largest shares of the overall increase. Trend heterogeneity was significant (p < 0.001), with trunk soft-tissue and head-and-neck sarcomas increasing the fastest. Findings were robust after excluding 2020 and in specified-site–only analyses. Conclusions: Mortality coded to sarcoma-related ICD-10 underlying-cause categories increased across all anatomically specified sites, with heterogeneous site-specific trends. Retroperitoneal/peritoneal and bone categories contributed most to the absolute increase, while trunk soft tissue and head and neck categories showed the steepest relative increases.
- 7 May 2026
- Published by American Society for Inclusion, Diversity, and Equity in Healthcare in ASIDE Oncology
- Vol. 1 (1) , 38-43
Open AccessDivergent Temporal Trends in Site-Specific Sarcoma Mortality in the United States, 1999–2020: A Population-Based Analysis
Background: Sarcomas are heterogeneous malignancies with prognoses that vary markedly by anatomical site. Whether population-level mortality trends differ across anatomical locations remains unclear. Methods: Sarcoma-related deaths in the United States from 1999 to 2020 were analyzed using the CDC WONDER Underlying Cause of Death database. ICD-10 codes classified deaths into six anatomical categories: bone, retroperitoneal/peritoneal, trunk soft tissue, extremity soft tissue, head and neck, and unspecified. Negative binomial regression models with a population offset estimated site-specific trends, and an interaction model tested heterogeneity across sites. Sensitivity analyses excluded 2020 and recalculated proportions among specified-site deaths only. Results: Nearly half of the deaths were coded to unspecified sites (49.8%), with no improvement over time. Among specified sites, bone accounted for the largest share (22.6%), followed by retroperitoneal/peritoneal sarcomas (15.1%). Overall mortality increased by 1.32% annually (IRR 1.013, 95% CI 1.012–1.014), with significant increases across all specified sites. Decomposition showed that retroperitoneal/peritoneal (43.5%) and bone (29.7%) sarcomas contributed the largest shares of the overall increase. Trend heterogeneity was significant (p < 0.001), with trunk soft-tissue and head-and-neck sarcomas increasing the fastest. Findings were robust after excluding 2020 and in specified-site–only analyses. Conclusions: Mortality coded to sarcoma-related ICD-10 underlying-cause categories increased across all anatomically specified sites, with heterogeneous site-specific trends. Retroperitoneal/peritoneal and bone categories contributed most to the absolute increase, while trunk soft tissue and head and neck categories showed the steepest relative increases.
- Open Access
- 28 February 2026
- Published by Institute of Lifestyle Medicine in Journal of Lifestyle Medicine
- Vol. 16 (1) , 32-38
Accelerated Muscle Strength Decline and Reduced Lean Mass in Adults with Treated Inflammatory Bowel Disease: A NHANES Study
Muhanad Alzahrani, Abdullah Alabbasi, Mohammed Sayes, Rayyan Fahad Hamoud Altemani, Ziyad Alzahrani, Faris Sultan. JLM 2026;16:32-8. https://doi.org/10.15280/jlm.2026.16.1.32
- 28 February 2026
- Published by Institute of Lifestyle Medicine in Journal of Lifestyle Medicine
- Vol. 16 (1) , 32-38
Open AccessAccelerated Muscle Strength Decline and Reduced Lean Mass in Adults with Treated Inflammatory Bowel Disease: A NHANES Study
Muhanad Alzahrani, Abdullah Alabbasi, Mohammed Sayes, Rayyan Fahad Hamoud Altemani, Ziyad Alzahrani, Faris Sultan. JLM 2026;16:32-8. https://doi.org/10.15280/jlm.2026.16.1.32